Clinical Trials
84 trialsTivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
MOMENT
Prostate Cancer Clinical Trials Consortium
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
OHSU Knight Cancer Institute
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
PREDICT
Alliance for Clinical Trials in Oncology
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
TALENT
Prostate Cancer Clinical Trials Consortium
DIVINE
Mayo Clinic
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
DICE
Cancer Trials Ireland
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Institutes of Health Clinical Center (CC)
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
University of Chicago
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
University of Southern California
CheckMate 9KD
Bristol-Myers Squibb
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Wake Forest University Health Sciences
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
STEEL
RTOG Foundation, Inc.
PROSTEP-002
CHU de Quebec-Universite Laval
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
ARACOG
Alliance Foundation Trials, LLC.
ARROW
Progenics Pharmaceuticals, Inc.
CDK4i
Pfizer
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Jonsson Comprehensive Cancer Center
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
ZZ-First
MedSIR
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Astellas Pharma Inc
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
Astellas Pharma Inc
ENACT
Astellas Pharma Inc
TEAM PC
Fundacion Oncosur
ANZadapt
Leiden University Medical Center
DIRECT
University Health Network, Toronto
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Astellas Pharma Inc
Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
University of Rochester
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Medical University of South Carolina
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
OHSU Knight Cancer Institute
BonEnza
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
CHEIRON
Santa Chiara Hospital
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo